Key facts
- Notable investors include SPRIM Global Investments.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Inhalyx Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Inhalyx Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Inhalyx Biotech
Operator of a biotechnology company intended to drive progress in respiratory medicine. The company specializes in inhaled therapies for respiratory diseases, including cystic fibrosis (CF) and non-CF bronchiectasis. Among its key treatments is colifin, enabling patients to get relief from their respiratory condition.
- Sector
- Healthcare
- HQ
- Melbourne, Australia
- Founded
- 2025
- Ownership
- Privately Held (backing)
Inhalyx Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Inhalyx Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Inhalyx Biotech in its N-PORT filings yet. We sweep new filings monthly.